Last reviewed · How we verify
Drug: salmeterol xinafoate
Drug: salmeterol xinafoate is a Small molecule drug developed by Neothetics, Inc. It is currently in Phase 2 development. Also known as: LIPO-202, Salmeterol.
At a glance
| Generic name | Drug: salmeterol xinafoate |
|---|---|
| Also known as | LIPO-202, Salmeterol |
| Sponsor | Neothetics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- ANTES B+ Clinical Trial (PHASE4)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Asthma Research in Children and Adolescents
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: salmeterol xinafoate CI brief — competitive landscape report
- Drug: salmeterol xinafoate updates RSS · CI watch RSS
- Neothetics, Inc portfolio CI
Frequently asked questions about Drug: salmeterol xinafoate
What is Drug: salmeterol xinafoate?
Drug: salmeterol xinafoate is a Small molecule drug developed by Neothetics, Inc.
Who makes Drug: salmeterol xinafoate?
Drug: salmeterol xinafoate is developed by Neothetics, Inc (see full Neothetics, Inc pipeline at /company/neothetics-inc).
Is Drug: salmeterol xinafoate also known as anything else?
Drug: salmeterol xinafoate is also known as LIPO-202, Salmeterol.
What development phase is Drug: salmeterol xinafoate in?
Drug: salmeterol xinafoate is in Phase 2.
Related
- Manufacturer: Neothetics, Inc — full pipeline
- Also known as: LIPO-202, Salmeterol
- Compare: Drug: salmeterol xinafoate vs similar drugs
- Pricing: Drug: salmeterol xinafoate cost, discount & access